Activating Autophagy as a Therapeutic Strategy for Parkinson’s Disease

• Published in: CNS drugs 2018, Vol.32 (1), p.1-11
• Main Authors: Fowler, Alan J., Moussa, Charbel E.-H.
• Format: Article
• Language: English
• Subjects: alpha-Synuclein - metabolism; Alzheimer's disease; Animal models; Animals; Antiparkinson Agents - pharmacology; Autophagy; Autophagy - drug effects; Brain; Cell culture; Cell division; Clinical trials; Defects; Drug Development - methods; Drug dosages; Drug Evaluation, Preclinical - methods; Humans; Kinases; Leading Article; Lewy bodies; Medicine; Medicine & Public Health; Mice; Movement disorders; Nervous system; Neurodegeneration; Neurodegenerative diseases; Neurology; Neurons; Neurosciences; Parkinson Disease - drug therapy; Parkinson Disease - physiopathology; Parkinson's disease; Phagocytosis; Pharmacotherapy; Protein folding; Proteins; Psychiatry; Psychopharmacology; Symptom management; Synuclein
• ISSN: 1172-7047; 1179-1934
• DOI: 10.1007/s40263-018-0497-5

Parkinson’s disease is a progressive neurodegenerative disease characterized by Lewy body pathology of which the primary constituent is aggregated misfolded alpha-synuclein protein. Currently, there are no clinical therapies for treatment of the underlying alpha-synuclein dysfunction and accumulation, and the standard of care for patients with Parkinson’s disease focuses only on symptom management, creating an immense therapeutic gap that needs to be filled. Defects in autophagy have been strongly implicated in Parkinson’s disease. Here, we review evidence from human, mouse, and cell culture studies to briefly explain these defects in autophagy in Parkinson’s disease and the necessity for autophagy to be carefully and precisely tuned to maintain neuron survival. We summarize recent experimental agents for treating alpha-synuclein accumulation in α-synuclein Parkinson’s disease and related synucleinopathies. Most of the efforts for developing experimental agents have focused on immunotherapeutic strategies, but we discuss why those efforts are misplaced. Finally, we emphasize why increasing autophagy flux for alpha-synuclein clearance is the most promising therapeutic strategy. Activating autophagy has been successful in preclinical models of Parkinson’s disease and yields promising results in clinical trials.